Abstract

The free fatty acid receptor 2 (FFAR2) is a deorphanized G-protein coupled receptor (GPCR) that is widely expressed in various tissues in the body. Previous studies have shown that the short-chain fatty acids (SCFAs) acetate, butyrate and propionate activate FFAR2, leading to changes in cellular function. SCFAs are gut microbial metabolites important in shaping and maintaining gut homeostasis, as well as impacting other cell functions. FFAR2 is found in pancreatic islets and has led to investigational studies for the treatment of metabolic diseases. Our study focuses on FFAR2 as a potential treatment for type 2 diabetes mellitus (T2DM). FFAR2 contributes to glucose-stimulated insulin secretion (GSIS) and its potential in therapy has not been fully explored. This study focused on the effects of GPCR agonists targeting the deorphanized free fatty acid receptor 2 via intracellular calcium assays. We investigated the effects of numerous GPCR agonists on FFAR2, with a specific focus on identifying agonists or allosteric modulators. Further analysis and testing are underway to pinpoint specific agonists as potential treatment options for T2DM.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.